Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$10.95 ▲ +0.08
(+0.74%)
MKT CAP: $383.6M • VOL: 180.6K
52W L $6 52W H $13
FENC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $44.6M | $47.5M | $21.3M |
| YoY Revenue Growth % | -6.1% | +123.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$6.3M | $2.6M | -$12.8M |
| Operating Margin % | -14.1% | 5.4% | -60.1% |
| Net Income (GAAP) | -$9.74B | -$436.0M | -$16.05B |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$12.5M | $27.0M | -$17.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$12.5M | $27.0M | -$17.1M |
| FCF Margin % | -27.9% | 56.8% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $36.8M | $26.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $35.5M | -$5.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FENC.